OKYO Pharma Starts 100-Patient Trial for Urcosimod
Ticker: OKYO · Form: 6-K · Filed: Sep 22, 2025 · CIK: 1849296
Sentiment: neutral
Topics: clinical-trial, drug-development, neurology
TL;DR
OKYO Pharma just kicked off a 100-patient trial for Urcosimod in eye pain. Big step for their drug.
AI Summary
On September 22, 2025, OKYO Pharma Ltd announced the initiation of a 100-patient, multi-center clinical trial for Urcosimod to treat Neuropathic Corneal Pain. This marks a significant step in the drug's registration pathway.
Why It Matters
This clinical trial is a crucial step for OKYO Pharma in advancing Urcosimod towards potential regulatory approval for treating neuropathic corneal pain, a condition with limited treatment options.
Risk Assessment
Risk Level: medium — Clinical trials are inherently risky, with outcomes dependent on efficacy and safety data, and regulatory approval is not guaranteed.
Key Numbers
- 100 — Patients (Number of participants in the multi-center clinical trial)
Key Players & Entities
- OKYO Pharma LTD (company) — Registrant
- Urcosimod (drug) — Investigational drug for neuropathic corneal pain
- September 22, 2025 (date) — Date of announcement and trial initiation
FAQ
What is the primary indication for Urcosimod in this trial?
The primary indication for Urcosimod in this trial is Neuropathic Corneal Pain.
What type of clinical trial is being initiated?
A 100-patient, multi-center clinical trial is being initiated.
When was this announcement made by OKYO Pharma?
The announcement was made on September 22, 2025.
What is the significance of this trial for Urcosimod?
This trial is part of the registration pathway for Urcosimod.
Where is OKYO Pharma LTD's principal executive office located?
OKYO Pharma LTD's principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
Filing Stats: 332 words · 1 min read · ~1 pages · Grade level 14.7 · Accepted 2025-09-22 08:30:04
Filing Documents
- form6-k.htm (6-K) — 21KB
- ex99-1.htm (EX-99.1) — 22KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001493152-25-014405.txt ( ) — 64KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: September 22, 2025 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated September 22, 2025 4